Imatinib and tyrosine kinase inhibition, in the management of BCR-ABL negative myeloproliferative disorders

open access to scientific and medical research

Average Article Statistics

23 Days

From submission to first editorial decision.

17 Days

From editorial acceptance to publication.

*Business days (Mon-Fri)

Rejection Rate

80 %

The above percentage of manuscripts have been rejected in the last 12 months.

60022

Papers Published

Submit Manuscript

Journal Email Alerts

Signup for Alerts

About Dove Press

Open access peer-reviewed scientific and medical journals.

Learn more

Open Access

Dove Medical Press is a member of the OAI.

Learn more

Reprints

Bulk reprints for the pharmaceutical industry.

Learn more

Promotional Article Monitoring

Register your specific details and specific drugs of interest and we will match the information you provide to articles from our extensive database and email PDF copies to you promptly.

Learn more

Social Media

Back to Journals » Biologics: Targets and Therapy » Volume 1 » Issue 2

Imatinib and tyrosine kinase inhibition, in the management of BCR-ABL negative myeloproliferative disorders

Total article views		Abstract views	HTML views	PDF downloads	Totals
4,530	Dovepress*	4,530	0+	2,077	4,530
4,530	Totals	4,530	0	2,077	4,530
*Since 15 November 2007 +Since July 2016

View citations on Google Scholar

In order to provide our website visitors and registered users with a service tailored to their individual preferences we use cookies to analyse visitor traffic and personalise content. You can learn about our use of cookies by reading our Privacy Policy. We also retain data in relation to our visitors and registered users for internal purposes and for sharing information with our business partners. You can learn about what data of yours we retain, how it is processed, who it is shared with and your right to have your data deleted by reading our Privacy Policy.

If you agree to our use of cookies and the contents of our Privacy Policy please click 'accept'.